CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
从 4 级 ICANS 中存活：一例病例报告及新兴管理策略讨论
英文原题：Surviving Grade 4 ICANS: A Case Report and Discussion of Emerging Management Strategies.
查看英文原题
Surviving Grade 4 ICANS: A Case Report and Discussion of Emerging Management Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法日益用于肿瘤及非肿瘤疾病。低级别神经毒性通常容易治疗，但重度神经毒性仍是临床难题，且常可致命。我们报告一例复发性急性淋巴细胞白血病年轻成人患者，发生4级免疫效应细胞相关神经毒性综合征（ICANS），表现为对一线治疗无应答的重度脑水肿。我们介绍了包括多线靶向免疫治疗和主动监测颅内压在内的治疗策略。患者存活，目前仍处于缓解状态，神经功能也获得有意义的恢复。随着CAR-T 细胞疗法应用不断增加，神经科医生需了解并做好准备，治疗这类可能致命的病例。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy is increasingly used in both oncologic and nononcologic conditions. Although low-grade neurotoxicity may be easily treated, severe neurotoxicity remains clinically challenging and many times fatal.
We present the case of a young adult with relapsed acute lymphoblastic leukemia who developed grade 4 immune effector cell-associated neurotoxicity syndrome (ICANS), manifesting as severe cerebral edema refractory to first-line therapies.
We share our treatment strategy consisting of multiple lines of targeted immunotherapy and proactive intracranial pressure monitoring. The patient survived and continues to remain in remission with meaningful neurologic recovery. Because of the growing use of chimeric antigen receptor T-cell therapies, neurologists need to be aware and ready to treat these potentially fatal cases.
论文信息
- 作者
- Jonokuchi AJ、Yu AW、Kaur G、Satwani P、Reshef R、Wesley SF
- 单位
- Department of Neurology, Columbia University Medical Center, New York, NY, USA.United States
- 文献类型
- 病例报告
- 期刊
- Journal of child neurology2025 Sep
- 原文标识
- PubMed 40370190 · DOI 10.1177/08830738251335055